Israeli Diagnostics Co EXALENZ Named as One-to-Watch in Deloitte Technology Fast 50™ Awards

EXALENZ Bioscience, a new company to our pages, has announced that it was named as one of the prestigious Deloitte Technology Fast 50, an annual ranking of the 50 fastest-growing technology companies in Israel for 2014. The company specializes in developing and marketing medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases.

Background

The Deloitte Technology 50 is a ranking of Israel’s 50 fastest-growing technology companies based on percentage growth over five years. The Fast 50 program honors business growth, technological innovation and Israeli entrepreneurial spirit. EXALENZ was honored at the Fast 50 2014 awards ceremony on September 21, 2014 in Tel Aviv, Israel.

Based in Israel, EXALENZ has built a broad footprint in the United States with over 300 medical centers offering its Hp-BreathID test to detect the potentially lethal H. pylori bacterium. Over the last five years, sales reached over ILS 40 million, and the last two years the company’s sales volume reached ILS 24.4 million.

Recently, EXALENZ reported that it is in discussions with several pharmaceutical companies to advance new diagnostic and monitoring tools for NASH (Nonalcoholic Steatohepatitis). In addition, EXALENZ is developing additional diagnostic and monitoring applications such as (CSPH) Clinically Significant Portal Hypertension – a dangerous condition that can occur in patients with cirrhosis of the liver, as well as a test for Hepatocellular Carcinoma (HCC).

Company comments

“We are proud to be honored as one of the fastest growing technology companies in Israel by Deloitte,” said Larry Cohen, CEO of EXALENZ. “Our strong growth over the last five years reflects our team’s success at executing and implementing our plan, as well as increased recognition of BreathID’s clinical benefits by our customers. The next few years we expect to see continued strong growth fueled by higher sales of BreathID systems in the US, and the anticipated introduction of new diagnostics aimed at significant liver indications such as NASH.”

Source: Exalenz Bioscience, PR Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *